Differences among HIV-1 subtypes in drug resistance against integrase inhibitors
- PMID: 27353185
- DOI: 10.1016/j.meegid.2016.06.047
Differences among HIV-1 subtypes in drug resistance against integrase inhibitors
Abstract
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been documented. Due to extensive and dynamic genetic diversity in different HIV-1 variants, significant differences in susceptibility to the INSTIs have been observed among HIV subtypes. This review summarizes what is known about this topic and discusses possible clinical implications.
Keywords: Drug resistance; HIV subtypes; Integrase inhibitors.
Copyright © 2016 Elsevier B.V. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
